Search

Displaying results 2381 - 2390 of 10000 in total
  1. Drug

    Echothiophate

    go.drugbank.com/drugs/DB01057
    ApprovedInvestigational

    A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.

    Synonyms: 2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodide
  2. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    of cGMP in the smooth muscle cells of the corpus cavernosum. … [A258318] The FDA approved the use of vardenafil for the treatment of erectile dysfunction in 2003.

    Categories: Drugs Used in Erectile Dysfunction
  3. Drug

    Dornase alfa

    go.drugbank.com/drugs/DB00003
    ApprovedInvestigational

    Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. … In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections.

  4. Drug

    Gadolinium

    go.drugbank.com/drugs/DB12091
    ApprovedInvestigationalWithdrawn

    Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act. … Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent.

  6. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. … Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli.

  7. Drug

    Mephentermine

    go.drugbank.com/drugs/DB01365
    ApprovedWithdrawn

    A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia.

  8. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  9. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.

  10. Drug

    Clorazepic acid

    go.drugbank.com/drugs/DB00628
    ApprovedIllicit

    Clorazepic acid (clorazepate) is a water-soluble benzodiazepine with muscle-relaxant and anticonvulsant actions effective in the treatment of anxiety. … In September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation.